Grey Street Capital’s Gilead Sciences GILD Stock Holding History

Grey Street Capital’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	$1.44M	Buy	+19,662	New	+$1.51M	0.2%	124

Other funds holding GILD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Grey Street Capital's GILD Position: Q1 2024 in Review

Grey Street Capital opened a new position in Gilead Sciences (GILD) in Q1 2024: 19,662 shares worth $1.44M. The stake represents 0.2% of the portfolio and ranks #124 among its holdings.

1,721 funds tracked by Wall St. Rank hold GILD as of Q1 2024.

Grey Street Capital held 19,662 shares of Gilead Sciences worth $1.44M as of Q1 2024.
Gilead Sciences was a new Grey Street Capital position in Q1 2024.
Gilead Sciences made up 0.2% of Grey Street Capital's portfolio in Q1 2024, its #124 holding.
1,721 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2024.

Based on Grey Street Capital's 13F filing for Q1 2024, filed 9 Aug 2024.